INS and familial pancreatic carcinoma: In the prevalent new-user design, HRs for pancreatic cancer in GLP-1RA users vs basal insulin users were 1.03 (95% CI, 0.72-1.47) over the full follow-up period, 1.13 (95% CI, 0.73-1.76) omitting the first year of follow-up, and 0.75 (95% CI, 0.37-1.53) omitting the first 4 years of follow-up (eTable 3 in Supplement 1).